Safety and immunogenicity of an investigational 4-component Staphylococcus aureus vaccine with or without AS03_B adjuvant: Results of a randomized phase I trial

References

• Lowy FD. Staphylococcus aureus infections. N Engl J Med 1998; 339:520-32; PMID:9709046; http://dx.doi.org/10.1056/NEJM199808203390806
   PubMed Web of Science ®Google Scholar
• Grundmann H, Aires-de-Sousa M, Boyce J, Tiemersma E. Emergence and resurgence of meticillin-resistant Staphylococcus aureus as a public-health threat. Lancet 2006; 368:874-85; PMID:16950365; http://dx.doi.org/10.1016/S0140-6736(06)68853-3
   PubMed Web of Science ®Google Scholar
• WHO. Antimicrobial resistance. Fact sheet N°194. Updated May 2013. Available at: http://www.who.int/mediacentre/factsheets/fs194/en/
   Google Scholar
• Wertheim HF, Vos MC, Ott A, van Belkum A, Voss A, Kluytmans JA, van Keulen PH, Vandenbroucke-Grauls CM, Meester MH, Verbrugh HA. Risk and outcome of nosocomial Staphylococcus aureus bacteraemia in nasal carriers versus non-carriers. Lancet 2004; 364:703-5; PMID:15325835; http://dx.doi.org/10.1016/S0140-6736(04)16897-9
   PubMed Web of Science ®Google Scholar
• Bagnoli F, Bertholet S, Grandi G. Inferring reasons for the failure of Staphylococcus aureus vaccines in clinical trials. Front Cell Infect Microbiol 2012; 2:16; PMID:22919608; http://dx.doi.org/10.3389/fcimb.2012.00016
   PubMed Web of Science ®Google Scholar
• Thakker M, Park JS, Carey V, Lee JC. Staphylococcus aureus serotype 5 capsular polysaccharide is antiphagocytic and enhances bacterial virulence in a murine bacteremia model. Infect Immun 1998; 66:5183-9; PMID:9784520
   PubMed Web of Science ®Google Scholar
• Foster TJ, Geoghegan JA, Ganesh VK, Hook M. Adhesion, invasion and evasion: the many functions of the surface proteins of Staphylococcus aureus. Nat Rev Microbiol 2014; 12:49-62; PMID:24336184; http://dx.doi.org/10.1038/nrmicro3161
   PubMed Web of Science ®Google Scholar
• Novick RP. Autoinduction and signal transduction in the regulation of staphylococcal virulence. Mol Microbiol 2003; 48:1429-49; PMID:12791129; http://dx.doi.org/10.1046/j.1365-2958.2003.03526.x
   PubMed Web of Science ®Google Scholar
• O'Riordan K, Lee JC. Staphylococcus aureus capsular polysaccharides. Clin Microbiol Rev 2004; 17:218-34; PMID:14726462; http://dx.doi.org/10.1128/CMR.17.1.218-234.2004
   PubMed Web of Science ®Google Scholar
• Foster TJ. Immune evasion by staphylococci. Nat Rev Microbiol 2005; 3:948-58; PMID:16322743; http://dx.doi.org/10.1038/nrmicro1289
   PubMed Web of Science ®Google Scholar
• Hair PS, Ward MD, Semmes OJ, Foster TJ, Cunnion KM. Staphylococcus aureus clumping factor A binds to complement regulator factor I and increases factor I cleavage of C3b. J Infect Dis 2008; 198:125-33; PMID:18544012; http://dx.doi.org/10.1086/588825
   PubMed Web of Science ®Google Scholar
• McCormick JK, Yarwood JM, Schlievert PM. Toxic shock syndrome and bacterial superantigens: an update. Annu Rev Microbiol 2001; 55:77-104; PMID:11544350; http://dx.doi.org/10.1146/annurev.micro.55.1.77
   PubMed Web of Science ®Google Scholar
• Postma B, Kleibeuker W, Poppelier MJ, Boonstra M, Van Kessel KP, Van Strijp JA, de Haas CJ. Residues 10-18 within the C5a receptor N terminus compose a binding domain for chemotaxis inhibitory protein of Staphylococcus aureus. J Biol Chem 2005; 280:2020-7; PMID:15542591; http://dx.doi.org/10.1074/jbc.M412230200
   PubMed Web of Science ®Google Scholar
• Silverman GJ, Goodyear CS. Confounding B-cell defences: lessons from a staphylococcal superantigen. Nat Rev Immunol 2006; 6:465-75; PMID:16724100; http://dx.doi.org/10.1038/nri1853
   PubMed Web of Science ®Google Scholar
• Peterson PK, Verhoef J, Sabath LD, Quie PG. Effect of protein A on staphylococcal opsonization. Infect Immun 1977; 15:760-4; PMID:870431
   PubMed Web of Science ®Google Scholar
• Wang J, Roderiquez G, Norcross MA. Control of adaptive immune responses by Staphylococcus aureus through IL-10, PD-L1, and TLR2. Sci Rep 2012; 2:606; PMID:22930672
   PubMed Web of Science ®Google Scholar
• Kim HK, Thammavongsa V, Schneewind O, Missiakas D. Recurrent infections and immune evasion strategies of Staphylococcus aureus. Curr Opin Microbiol 2012; 15:92-9; PMID:22088393; http://dx.doi.org/10.1016/j.mib.2011.10.012
   PubMed Web of Science ®Google Scholar
• Proctor RA, von Eiff C, Kahl BC, Becker K, McNamara P, Herrmann M, Peters G. Small colony variants: a pathogenic form of bacteria that facilitates persistent and recurrent infections. Nat Rev Microbiol 2006; 4:295-305; PMID:16541137; http://dx.doi.org/10.1038/nrmicro1384
   PubMed Web of Science ®Google Scholar
• Thurlow LR, Hanke ML, Fritz T, Angle A, Aldrich A, Williams SH, Engebretsen IL, Bayles KW, Horswill AR, Kielian T. Staphylococcus aureus biofilms prevent macrophage phagocytosis and attenuate inflammation in vivo. J Immunol 2011; 186:6585-96; PMID:21525381; http://dx.doi.org/10.4049/jimmunol.1002794
   PubMed Web of Science ®Google Scholar
• Proctor RA. Is there a future for a Staphylococcus aureus vaccine? Vaccine 2012; 30:2921-7; PMID:22115633; http://dx.doi.org/10.1016/j.vaccine.2011.11.006
   PubMed Web of Science ®Google Scholar
• Schaffer AC, Lee JC. Staphylococcal vaccines and immunotherapies. Infect Dis Clin North Am 2009; 23:153-71; PMID:19135920; http://dx.doi.org/10.1016/j.idc.2008.10.005
   PubMed Web of Science ®Google Scholar
• Daum RS, Spellberg B. Progress toward a Staphylococcus aureus vaccine. Clin Infect Dis 2012; 54:560-7; PMID:22186773; http://dx.doi.org/10.1093/cid/cir828
   PubMed Web of Science ®Google Scholar
• Shinefield H, Black S, Fattom A, Horwith G, Rasgon S, Ordonez J, Yeoh H, Law D, Robbins JB, Schneerson R, et al. Use of a Staphylococcus aureus conjugate vaccine in patients receiving hemodialysis. N Engl J Med 2002; 346:491-6; PMID:11844850; http://dx.doi.org/10.1056/NEJMoa011297
   PubMed Web of Science ®Google Scholar
• Fattom A, Matalon A, Buerkert J, Taylor K, Damaso S, Boutriau D. Efficacy profile of a bivalent Staphylococcus aureus glycoconjugate vaccine in adults on hemodialysis: phase III randomized study. Hum Vaccin Immunother 2014; e34414.
   Google Scholar
• Creech CB, 2nd Johnson BG, Alsentzer AR, Hohenboken M, Edwards KM, Talbot TR, 3rd. Vaccination as infection control: a pilot study to determine the impact of Staphylococcus aureus vaccination on nasal carriage. Vaccine 2009; 28:256-60; PMID:19799842; http://dx.doi.org/10.1016/j.vaccine.2009.09.088
   PubMed Web of Science ®Google Scholar
• Fowler VG, Allen KB, Moreira ED, Moustafa M, Isgro F, Boucher HW, Corey GR, Carmeli Y, Betts R, Hartzel JS, et al. Effect of an investigational vaccine for preventing Staphylococcus aureus infections after cardiothoracic surgery: a randomized trial. JAMA 2013; 309:1368-78; PMID:23549582; http://dx.doi.org/10.1001/jama.2013.3010
   PubMed Web of Science ®Google Scholar
• Spellberg B, Daum R. A new view on development of a Staphylococcus aureus vaccine: insights from mice and men. Hum Vaccin 2010; 6:857-9; PMID:20930569; http://dx.doi.org/10.4161/hv.6.10.12469
   PubMed Web of Science ®Google Scholar
• Anderson AS, Miller AA, Donald RG, Scully IL, Nanra JS, Cooper D, Jansen KU. Development of a multicomponent Staphylococcus aureus vaccine designed to counter multiple bacterial virulence factors. Hum Vaccin Immunother 2012; 8:1585-94; PMID:22922765; http://dx.doi.org/10.4161/hv.21872
   PubMed Web of Science ®Google Scholar
• Wacker M, Wang L, Kowarik M, Dowd M, Lipowsky G, Faridmoayer A, Shields K, Park S, Alaimo C, Kelley KA, et al. Prevention of Staphylococcus aureus infections by glycoprotein vaccines synthesized in Escherichia coli. J Infect Dis 2014; 209:1551-61; PMID:24308931; http://dx.doi.org/10.1093/infdis/jit800
   PubMed Web of Science ®Google Scholar
• Watts A, Ke D, Wang Q, Pillay A, Nicholson-Weller A, Lee JC. Staphylococcus aureus strains that express serotype 5 or serotype 8 capsular polysaccharides differ in virulence. Infect Immun 2005; 73:3502-11; PMID:15908379; http://dx.doi.org/10.1128/IAI.73.6.3502-3511.2005
   PubMed Web of Science ®Google Scholar
• Richmond P, Borrow R, Goldblatt D, Findlow J, Martin S, Morris R, Cartwright K, Miller E. Ability of 3 different meningococcal C conjugate vaccines to induce immunologic memory after a single dose in UK toddlers. J Infect Dis 2001; 183:160-3; PMID:11078484; http://dx.doi.org/10.1086/317646
   PubMed Web of Science ®Google Scholar
• Bhakdi S, Tranum-Jensen J. Alpha-toxin of Staphylococcus aureus. Microbiol Rev 1991; 55:733-51; PMID:1779933
   PubMedGoogle Scholar
• Bubeck Wardenburg J, Schneewind O. Vaccine protection against Staphylococcus aureus pneumonia. J Exp Med 2008; 205:287-94; PMID:18268041; http://dx.doi.org/10.1084/jem.20072208
   PubMed Web of Science ®Google Scholar
• Jarry TM, Memmi G, Cheung AL. The expression of alpha-haemolysin is required for Staphylococcus aureus phagosomal escape after internalization in CFT-1 cells. Cell Microbiol 2008; 10:1801-14; PMID:18466345; http://dx.doi.org/10.1111/j.1462-5822.2008.01166.x
   PubMedGoogle Scholar
• Kubica M, Guzik K, Koziel J, Zarebski M, Richter W, Gajkowska B, Golda A, Maciag-Gudowska A, Brix K, Shaw L, et al. A potential new pathway for Staphylococcus aureus dissemination: the silent survival of S. aureus phagocytosed by human monocyte-derived macrophages. PLoS One 2008; 3:e1409; PMID:18183290; http://dx.doi.org/10.1371/journal.pone.0001409
   PubMed Web of Science ®Google Scholar
• Loughman A, Fitzgerald JR, Brennan MP, Higgins J, Downer R, Cox D, Foster TJ. Roles for fibrinogen, immunoglobulin and complement in platelet activation promoted by Staphylococcus aureus clumping factor A. Mol Microbiol 2005; 57:804-18; PMID:16045623; http://dx.doi.org/10.1111/j.1365-2958.2005.04731.x
   PubMed Web of Science ®Google Scholar
• Brady RA, Mocca CP, Burns DL. Immunogenicity analysis of Staphylococcus aureus clumping factor A genetic variants. Clin Vaccine Immunol 2013; 20:1338-40; PMID:23803901; http://dx.doi.org/10.1128/CVI.00275-13
   PubMedGoogle Scholar
• Adhikari RP, Ajao AO, Aman MJ, Karauzum H, Sarwar J, Lydecker AD, Johnson JK, Nguyen C, Chen WH, Roghmann MC. Lower antibody levels to Staphylococcus aureus exotoxins are associated with sepsis in hospitalized adults with invasive S. aureus infections. J Infect Dis 2012; 206:915-23; PMID:22807524; http://dx.doi.org/10.1093/infdis/jis462
   PubMed Web of Science ®Google Scholar
• Fritz SA, Tiemann KM, Hogan PG, Epplin EK, Rodriguez M, Al-Zubeidi DN, Bubeck Wardenburg J, Hunstad DA. A serologic correlate of protective immunity against community-onset Staphylococcus aureus infection. Clin Infect Dis 2013; 56:1554-61; PMID:23446627; http://dx.doi.org/10.1093/cid/cit123
   PubMed Web of Science ®Google Scholar
• Adhikari RP, Karauzum H, Sarwar J, Abaandou L, Mahmoudieh M, Boroun AR, Vu H, Nguyen T, Devi VS, Shulenin S, et al. Novel structurally designed vaccine for S. aureus alpha-hemolysin: protection against bacteremia and pneumonia. PLoS One 2012; 7:e38567; PMID:22701668; http://dx.doi.org/10.1371/journal.pone.0038567
   PubMed Web of Science ®Google Scholar
• Kennedy AD, Bubeck Wardenburg J, Gardner DJ, Long D, Whitney AR, Braughton KR, Schneewind O, DeLeo FR. Targeting of alpha-hemolysin by active or passive immunization decreases severity of USA300 skin infection in a mouse model. J Infect Dis 2010; 202:1050-8; PMID:20726702; http://dx.doi.org/10.1086/656043
   PubMed Web of Science ®Google Scholar
• Mocca CP, Brady RA, Burns DL. Role of Antibodies in Protection Elicited by Active Vaccination with Genetically Inactivated Alpha Hemolysin in a Mouse Model of Staphylococcus aureus Skin and Soft Tissue Infections. Clin Vaccine Immunol 2014; 21:622-7; PMID:24574539; http://dx.doi.org/10.1128/CVI.00051-14
   PubMed Web of Science ®Google Scholar
• Lattar SM, Noto Llana M, Denoel P, Germain S, Buzzola FR, Lee JC, Sordelli DO. Protein antigens increase the protective efficacy of a capsule-based vaccine against Staphylococcus aureus in a rat model of osteomyelitis. Infect Immun 2014; 82:83-91; PMID:24126523; http://dx.doi.org/10.1128/IAI.01050-13
   PubMed Web of Science ®Google Scholar
• Tuchscherr LP, Buzzola FR, Alvarez LP, Lee JC, Sordelli DO. Antibodies to capsular polysaccharide and clumping factor A prevent mastitis and the emergence of unencapsulated and small-colony variants of Staphylococcus aureus in mice. Infect Immun 2008; 76:5738-44; PMID:18809660; http://dx.doi.org/10.1128/IAI.00874-08
   PubMed Web of Science ®Google Scholar
• Gong R, Hu C, Xu H, Guo A, Chen H, Zhang G, Shi L. Evaluation of clumping factor A binding region A in a subunit vaccine against Staphylococcus aureus-induced mastitis in mice. Clin Vaccine Immunol 2010; 17:1746-52; PMID:20826613; http://dx.doi.org/10.1128/CVI.00162-10
   PubMedGoogle Scholar
• Josefsson E, Higgins J, Foster TJ, Tarkowski A. Fibrinogen binding sites P336 and Y338 of clumping factor A are crucial for Staphylococcus aureus virulence. PLoS One 2008; 3:e2206; http://dx.doi.org/10.1371/journal.pone.0002206
   PubMed Web of Science ®Google Scholar
• Narita K, Hu DL, Mori F, Wakabayashi K, Iwakura Y, Nakane A. Role of interleukin-17A in cell-mediated protection against Staphylococcus aureus infection in mice immunized with the fibrinogen-binding domain of clumping factor A. Infect Immun 2010; 78:4234-42; PMID:20679443; http://dx.doi.org/10.1128/IAI.00447-10
   PubMed Web of Science ®Google Scholar
• Dantes R, Mu Y, Belflower R, Aragon D, Dumyati G, Harrison LH, Lessa FC, Lynfield R, Nadle J, Petit S, et al. National burden of invasive methicillin-resistant Staphylococcus aureus infections, United States, 2011. JAMA Intern Med 2013; 173:1970-8; PMID:24043270
   PubMed Web of Science ®Google Scholar
• Leroux-Roels I, Borkowski A, Vanwolleghem T, Drame M, Clement F, Hons E, Devaster JM, Leroux-Roels G. Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial. Lancet 2007; 370:580-9; PMID:17707753; http://dx.doi.org/10.1016/S0140-6736(07)61297-5
   PubMed Web of Science ®Google Scholar
• Leroux-Roels I, Bernhard R, Gerard P, Drame M, Hanon E, Leroux-Roels G. Broad Clade 2 cross-reactive immunity induced by an adjuvanted clade 1 rH5N1 pandemic influenza vaccine. PLoS One 2008; 3:e1665; PMID:18301743; http://dx.doi.org/10.1371/journal.pone.0001665
   PubMed Web of Science ®Google Scholar
• Morel S, Didierlaurent A, Bourguignon P, Delhaye S, Baras B, Jacob V, Planty C, Elouahabi A, Harvengt P, Carlsen H, et al. Adjuvant System AS03 containing alpha-tocopherol modulates innate immune response and leads to improved adaptive immunity. Vaccine 2011; 29:2461-73; PMID:21256188; http://dx.doi.org/10.1016/j.vaccine.2011.01.011
   PubMed Web of Science ®Google Scholar
• Roman F, Clement F, Dewe W, Walravens K, Maes C, Willekens J, De Boever F, Hanon E, Leroux-Roels G. Effect on cellular and humoral immune responses of the AS03 adjuvant system in an A/H1N1/2009 influenza virus vaccine administered to adults during two randomized controlled trials. Clin Vaccine Immunol 2011; 18:835-43; http://dx.doi.org/10.1128/CVI.00480-10
   PubMed Web of Science ®Google Scholar
• Berglund J, Vink P, Tavares Da Silva F, Lestrate P, Boutriau D. Safety, immunogenicity, and antibody persistence following an investigational Streptococcus pneumoniae and Haemophilus influenzae triple-protein vaccine in a phase 1 randomized controlled study in healthy adults. Clin Vaccine Immunol 2014; 21:56-65; PMID:24173029; http://dx.doi.org/10.1128/CVI.00430-13
   PubMed Web of Science ®Google Scholar
• Fattom AI, Horwith G, Fuller S, Propst M, Naso R. Development of StaphVAX, a polysaccharide conjugate vaccine against S. aureus infection: from the lab bench to phase III clinical trials. Vaccine 2004; 22:880-7; PMID:15040941; http://dx.doi.org/10.1016/j.vaccine.2003.11.034
   PubMed Web of Science ®Google Scholar
• Decker MD, Edwards KM, Bradley R, Palmer P. Comparative trial in infants of four conjugate Haemophilus influenzae type b vaccines. J Pediatr 1992; 120:184-9; PMID:1735812; http://dx.doi.org/10.1016/S0022-3476(05)80424-X
   PubMed Web of Science ®Google Scholar
• Croxtall JD, Dhillon S. Meningococcal quadrivalent (serogroups A, C, W135 and Y) tetanus toxoid conjugate vaccine (Nimenrix). Drugs 2012; 72:2407-30; PMID:23231026; http://dx.doi.org/10.2165/11209580-000000000-00000
   PubMed Web of Science ®Google Scholar
• Prymula R, Schuerman L. 10-valent pneumococcal nontypeable Haemophilus influenzae PD conjugate vaccine: Synflorix. Expert Rev Vaccines 2009; 8:1479-500; PMID:19863240; http://dx.doi.org/10.1586/erv.09.113
   PubMed Web of Science ®Google Scholar
• Langley JM, Frenette L, Ferguson L, Riff D, Sheldon E, Risi G, Johnson C, Li P, Kenney R, Innis B, et al. Safety and cross-reactive immunogenicity of candidate AS03-adjuvanted prepandemic H5N1 influenza vaccines: a randomized controlled phase 1/2 trial in adults. J Infect Dis 2010; 201:1644-53; PMID:20423222; http://dx.doi.org/10.1086/652701
   PubMed Web of Science ®Google Scholar
• McElhaney JE, Beran J, Devaster JM, Esen M, Launay O, Leroux-Roels G, Ruiz-Palacios GM, van Essen GA, Caplanusi A, Claeys C, et al. AS03-adjuvanted versus non-adjuvanted inactivated trivalent influenza vaccine against seasonal influenza in elderly people: a phase 3 randomised trial. Lancet Infect Dis 2013; 13:485-96; PMID:23518156; http://dx.doi.org/10.1016/S1473-3099(13)70046-X
   PubMed Web of Science ®Google Scholar
• Leroux-Roels G, Marchant A, Levy J, Van Damme P, Schwarz T, Horsmans Y, Kremsner P, Gabor J, Esen M, Carletti I, et al. Learnings from clinical assessment of innate responses induced by several adjuvants combined with HBsAg model antigen. Keystone Symp Immunol Mech Vaccin, Ottawa, Canada, 13 to 18 Dec 2012, P1045.
   Google Scholar
• Fattom A, Schneerson R, Watson DC, Karakawa WW, Fitzgerald D, Pastan I, Li X, Shiloach J, Bryla DA, Robbins JB. Laboratory and clinical evaluation of conjugate vaccines composed of Staphylococcus aureus type 5 and type 8 capsular polysaccharides bound to Pseudomonas aeruginosa recombinant exoprotein A. Infect Immun 1993; 61:1023-32; PMID:8432585
   PubMed Web of Science ®Google Scholar
• Welch PG, Fattom A, Moore J, Jr., Schneerson R, Shiloach J, Bryla DA, Li X, Robbins JB. Safety and immunogenicity of Staphylococcus aureus type 5 capsular polysaccharide-Pseudomonas aeruginosa recombinant exoprotein A conjugate vaccine in patients on hemodialysis. J Am Soc Nephrol 1996; 7:247-53; PMID:8785394
   PubMed Web of Science ®Google Scholar
• Landrum M, Lalani T, Niknian M, Maguire J, Hospenthal D, Fattom A, Taylor K, Fraser J, Wilkins K, Ellis M, et al. A Randomized, Multi-Center Trial to Evaluate the Safety and Immunogenicity of Staphylococcus aureus Toxoids, rAT and rLukS-PV, in Healthy Volunteers. IDSA Oct 21 2011, P718.
   Google Scholar
• Richmond P, Nissen M, Marshall H, Shakib S, Hodsman P, Jiang Q, Rill D, Baber J, Eiden J, Jansen KU, et al. A randomised, placebo controlled phase 1 first-in-human study of a novel 3-antigen Staphylococcus aureus vaccine in healthy adults, poster LB2769. Proceedings of the 21st European Congress of Clinical Microbiology and Infectious diseases, 07 – 10 May 2011, Milan, Italy.
   Google Scholar
• Frenck R, Buddy Creech C, Sheldon E, Seiden DJ, Kankam M, Baber J, Zito E, Hubler R, Eiden J, Severs JM, et al. Safety, tolerability, and immunogenicity of a novel 4-antigen Staphylococcus aureus vaccine (sa4ag) in healthy adults: results of a randomized, placebo-controlled first-in-human phase 1/2 study, ePoster 134. 24th European Congress of Clinical Microbiology and Infectious diseases, 10 – 13 May 2014, Barcelona, Spain.
   Google Scholar
• Campbell JD, Edelman R, King JC, Jr., Papa T, Ryall R, Rennels MB. Safety, reactogenicity, and immunogenicity of a tetravalent meningococcal polysaccharide-diphtheria toxoid conjugate vaccine given to healthy adults. J Infect Dis 2002; 186:1848-51; PMID:12447774; http://dx.doi.org/10.1086/345763
   PubMed Web of Science ®Google Scholar
• Knuf M, Kowalzik F, Kieninger D. Comparative effects of carrier proteins on vaccine-induced immune response. Vaccine 2011; 29:4881-90; PMID:21549783; http://dx.doi.org/10.1016/j.vaccine.2011.04.053
   PubMed Web of Science ®Google Scholar
• Hawkins J, Kodali S, Matsuka YV, McNeil LK, Mininni T, Scully IL, Vernachio JH, Severina E, Girgenti D, Jansen KU, et al. A recombinant clumping factor A-containing vaccine induces functional antibodies to Staphylococcus aureus that are not observed after natural exposure. Clin Vaccine Immunol 2012; 19:1641-50; PMID:22896688; http://dx.doi.org/10.1128/CVI.00354-12
   PubMed Web of Science ®Google Scholar
• Lin L, Ibrahim AS, Xu X, Farber JM, Avanesian V, Baquir B, Fu Y, French SW, Edwards JE, Jr., Spellberg B. Th1-Th17 cells mediate protective adaptive immunity against Staphylococcus aureus and Candida albicans infection in mice. PLoS Pathog 2009; 5:e1000703; PMID:20041174; http://dx.doi.org/10.1371/journal.ppat.1000703
   PubMed Web of Science ®Google Scholar
• Minegishi Y, Karasuyama H. Defects in Jak-STAT-mediated cytokine signals cause hyper-IgE syndrome: lessons from a primary immunodeficiency. Int Immunol 2009; 21:105-12; PMID:19088064; http://dx.doi.org/10.1093/intimm/dxn134
   PubMed Web of Science ®Google Scholar
• Minegishi Y, Saito M. Molecular mechanisms of the immunological abnormalities in hyper-IgE syndrome. Ann N Y Acad Sci 2011; 1246:34-40; PMID:22236428; http://dx.doi.org/10.1111/j.1749-6632.2011.06280.x
   PubMedGoogle Scholar
• Minegishi Y, Saito M, Nagasawa M, Takada H, Hara T, Tsuchiya S, Agematsu K, Yamada M, Kawamura N, Ariga T, et al. Molecular explanation for the contradiction between systemic Th17 defect and localized bacterial infection in hyper-IgE syndrome. J Exp Med 2009; 206:1291-301; PMID:19487419; http://dx.doi.org/10.1084/jem.20082767
   PubMed Web of Science ®Google Scholar
• de Beaucoudrey L, Puel A, Filipe-Santos O, Cobat A, Ghandil P, Chrabieh M, Feinberg J, von Bernuth H, Samarina A, Janniere L, et al. Mutations in STAT3 and IL12RB1 impair the development of human IL-17-producing T cells. J Exp Med 2008; 205:1543-50; PMID:18591412; http://dx.doi.org/10.1084/jem.20080321
   PubMed Web of Science ®Google Scholar
• Senthilkumar A, Kumar S, Sheagren JN. Increased incidence of Staphylococcus aureus bacteremia in hospitalized patients with acquired immunodeficiency syndrome. Clin Infect Dis 2001; 33:1412-6; PMID:11565083; http://dx.doi.org/10.1086/322656
   PubMed Web of Science ®Google Scholar
• Cho SH, Strickland I, Tomkinson A, Fehringer AP, Gelfand EW, Leung DY. Preferential binding of Staphylococcus aureus to skin sites of Th2-mediated inflammation in a murine model. J Invest Dermatol 2001; 116:658-63; PMID:11348452; http://dx.doi.org/10.1046/j.0022-202x.2001.01331.x
   PubMed Web of Science ®Google Scholar
• Ong PY, Ohtake T, Brandt C, Strickland I, Boguniewicz M, Ganz T, Gallo RL, Leung DY. Endogenous antimicrobial peptides and skin infections in atopic dermatitis. N Engl J Med 2002; 347:1151-60; PMID:12374875; http://dx.doi.org/10.1056/NEJMoa021481
   PubMed Web of Science ®Google Scholar
• Harper EG, Guo C, Rizzo H, Lillis JV, Kurtz SE, Skorcheva I, Purdy D, Fitch E, Iordanov M, Blauvelt A. Th17 cytokines stimulate CCL20 expression in keratinocytes in vitro and in vivo: implications for psoriasis pathogenesis. J Invest Dermatol 2009; 129:2175-83; PMID:19295614; http://dx.doi.org/10.1038/jid.2009.65
   PubMed Web of Science ®Google Scholar
• Hedrick MN, Lonsdorf AS, Shirakawa AK, Richard Lee CC, Liao F, Singh SP, Zhang HH, Grinberg A, Love PE, Hwang ST, et al. CCR6 is required for IL-23-induced psoriasis-like inflammation in mice. J Clin Invest 2009; 119:2317-29
   PubMed Web of Science ®Google Scholar
• Niebuhr M, Gathmann M, Scharonow H, Mamerow D, Mommert S, Balaji H, Werfel T. Staphylococcal alpha-toxin is a strong inducer of interleukin-17 in humans. Infect Immun 2011; 79:1615-22; PMID:21245272; http://dx.doi.org/10.1128/IAI.00958-10
   PubMedGoogle Scholar
• Breuer K, Wittmann M, Kempe K, Kapp A, Mai U, Dittrich-Breiholz O, Kracht M, Mrabet-Dahbi S, Werfel T. Alpha-toxin is produced by skin colonizing Staphylococcus aureus and induces a T helper type 1 response in atopic dermatitis. Clin Exp Allergy 2005; 35:1088-95; PMID:16120092; http://dx.doi.org/10.1111/j.1365-2222.2005.02295.x
   PubMed Web of Science ®Google Scholar
• Moris P, van der Most R, Leroux-Roels I, Clement F, Drame M, Hanon E, Leroux-Roels GG, Van Mechelen M. H5N1 influenza vaccine formulated with AS03 A induces strong cross-reactive and polyfunctional CD4 T-cell responses. J Clin Immunol 2011; 31:443-54; PMID:21174144; http://dx.doi.org/10.1007/s10875-010-9490-6
   PubMed Web of Science ®Google Scholar
• Van Damme P, Kafeja F, Bambure V, Hanon E, Moris P, Roman F, Gillard P. Long-term persistence of humoral and cellular immune responses induced by an AS03A-adjuvanted H1N1 2009 influenza vaccine: an open-label, randomized study in adults aged 18-60 years and older. Hum Vaccin Immunother 2013; 9:1512-22; PMID:23571166; http://dx.doi.org/10.4161/hv.24504
   PubMed Web of Science ®Google Scholar
• Rumke HC, Richardus JH, Rombo L, Pauksens K, Plassmann G, Durand C, Devaster JM, Dewe W, Oostvogels L. Selection of an adjuvant for seasonal influenza vaccine in elderly people: modelling immunogenicity from a randomized trial. BMC Infect Dis 2013; 13:348; PMID:23890405; http://dx.doi.org/10.1186/1471-2334-13-348
   PubMed Web of Science ®Google Scholar
• Miller LS, Cho JS. Immunity against Staphylococcus aureus cutaneous infections. Nat Rev Immunol 2011; 11:505-18; PMID:21720387; http://dx.doi.org/10.1038/nri3010
   PubMed Web of Science ®Google Scholar
• Cua DJ, Tato CM. Innate IL-17-producing cells: the sentinels of the immune system. Nat Rev Immunol 2010; 10:479-89; PMID:20559326
   PubMed Web of Science ®Google Scholar
• Korn T, Bettelli E, Oukka M, Kuchroo VK. IL-17 and Th17 Cells. Annu Rev Immunol 2009; 27:485-517; PMID:19132915; http://dx.doi.org/10.1146/annurev.immunol.021908.132710
   PubMed Web of Science ®Google Scholar
• McNeela EA, Burke A, Neill DR, Baxter C, Fernandes VE, Ferreira D, Smeaton S, El-Rachkidy R, McLoughlin RM, Mori A, et al. Pneumolysin activates the NLRP3 inflammasome and promotes proinflammatory cytokines independently of TLR4. PLoS Pathog 2010; 6:e1001191
   PubMed Web of Science ®Google Scholar
• Olliver M, Hiew J, Mellroth P, Henriques-Normark B, Bergman P. Human monocytes promote Th1 and Th17 responses to Streptococcus pneumoniae. Infect Immun 2011; 79:4210-7; PMID:21788380; http://dx.doi.org/10.1128/IAI.05286-11
   PubMedGoogle Scholar
• Zielinski CE, Mele F, Aschenbrenner D, Jarrossay D, Ronchi F, Gattorno M, Monticelli S, Lanzavecchia A, Sallusto F. Pathogen-induced human TH17 cells produce IFN-gamma or IL-10 and are regulated by IL-1beta. Nature 2012; 484:514-8; PMID:22466287; http://dx.doi.org/10.1038/nature10957
   PubMed Web of Science ®Google Scholar
• Chlibek R, Bayas JM, Collins H, de la Pinta ML, Ledent E, Mols JF, Heineman TC. Safety and immunogenicity of an AS01-adjuvanted varicella-zoster virus subunit candidate vaccine against herpes zoster in adults >=50 years of age. J Infect Dis 2013; 208:1953-61; PMID:23904292; http://dx.doi.org/10.1093/infdis/jit365
   PubMed Web of Science ®Google Scholar
• Montoya J, Solon JA, Cunanan SR, Acosta L, Bollaerts A, Moris P, Janssens M, Jongert E, Demoitie MA, Mettens P, et al. A randomized, controlled dose-finding Phase II study of the M72/AS01 candidate tuberculosis vaccine in healthy PPD-positive adults. J Clin Immunol 2013; 33:1360-75; PMID:24142232
   PubMed Web of Science ®Google Scholar
• Vandepapeliere P, Horsmans Y, Moris P, Van Mechelen M, Janssens M, Koutsoukos M, Van Belle P, Clement F, Hanon E, Wettendorff M, et al. Vaccine adjuvant systems containing monophosphoryl lipid A and QS21 induce strong and persistent humoral and T cell responses against hepatitis B surface antigen in healthy adult volunteers. Vaccine 2008; 26:1375-86; PMID:18272264; http://dx.doi.org/10.1016/j.vaccine.2007.12.038
   PubMed Web of Science ®Google Scholar
• Round JL, Lee SM, Li J, Tran G, Jabri B, Chatila TA, Mazmanian SK. The Toll-like receptor 2 pathway establishes colonization by a commensal of the human microbiota. Science 2011; 332:974-7; PMID:21512004; http://dx.doi.org/10.1126/science.1206095
   PubMed Web of Science ®Google Scholar
• Schreiner J, Kretschmer D, Klenk J, Otto M, Buhring HJ, Stevanovic S, Wang JM, Beer-Hammer S, Peschel A, Autenrieth SE. Staphylococcus aureus phenol-soluble modulin peptides modulate dendritic cell functions and increase in vitro priming of regulatory T cells. J Immunol 2013; 190:3417-26; PMID:23460735; http://dx.doi.org/10.4049/jimmunol.1202563
   PubMed Web of Science ®Google Scholar
• Food and Drug A. Guidance for Industry. Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials. Available at: http://wwwfdagov/downloads/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/Vaccines/ucm091977pdf2007
   Google Scholar